Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease.
Gong J, He G, Wang C, Bartlett C, Panjwani N, Mastromatteo S, Lin F, Keenan K, Avolio J, Halevy A, Shaw M, Esmaeili M, Côté-Maurais G, Adam D, Bégin S, Bjornson C, Chilvers M, Reisman J, Price A, Parkins M, van Wylick R, Berthiaume Y, Bilodeau L, Mateos-Corral D, Hughes D, Smith MJ, Morrison N, Brusky J, Tullis E, Stephenson AL, Quon BS, Wilcox P, Leung WM, Solomon M, Sun L, Brochiero E, Moraes TJ, Gonska T, Ratjen F, Rommens JM, Strug LJ.
Gong J, et al. Among authors: esmaeili m.
NPJ Genom Med. 2022 Apr 8;7(1):28. doi: 10.1038/s41525-022-00299-9.
NPJ Genom Med. 2022.
PMID: 35396391
Free PMC article.